Orphan nuclear receptor Nur77 is a novel negative regulator of endothelin-1 expression in vascular endothelial cells

Journal of Molecular and Cellular Cardiology

Volumn 77, Issue , 2014, Pages 20-28

  Qin, Qing ^a,b   Chen, Ming ^a   Yi, Bing ^a   You, Xiaohua ^a   Yang, Ping ^a   Sun, Jianxin ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

AP 1; C Jun; Endothelin 1; Nur77; Transcription

Indexed keywords

ENDOTHELIN 1; MERCAPTOPURINE; MESSENGER RNA; NUCLEAR RECEPTOR NUR77; PROTEIN C JUN; THROMBIN; NR4A1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; 129 MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; GENE SILENCING; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; ENDOTHELIN-1; GENE SILENCING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC;

EID: 84908406483     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.09.027     Document Type: Article

References (43)

1. Abraham D., Dashwood M. Endothelin-role in vascular disease. Rheumatology (Oxford) 2008, 47(Suppl. 5):v23-v24.
2. Iglarz M., Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 2007, 50:621-628.
3. Seo B., Oemar B.S., Siebenmann R., von Segesser L., Luscher T.F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994, 89:1203-1208.
4. Luscher T.F., Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000, 102:2434-2440.
5. Mazzuca M.Q., Khalil R.A. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol 2012, 84:147-162.
6. Barton M. Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr Hypertens Rep 2000, 2:84-91.
7. Vignon-Zellweger N., Heiden S., Miyauchi T., Emoto N. Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci 2012, 91:490-500.
8. Lerman A., Edwards B.S., Hallett J.W., Heublein D.M., Sandberg S.M., Burnett J.C. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991, 325:997-1001.
9. Zeiher A.M., Ihling C., Pistorius K., Schachinger V., Schaefer H.E. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994, 344:1405-1406.
10. Simeone S.M., Li M.W., Paradis P., Schiffrin E.L. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol Genomics 2011, 43:148-160.
11. Galie N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004, 61:227-237.
12. Rubin L.J. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci 2012, 91:517-521.
13. Stow L.R., Jacobs M.E., Wingo C.S., Cain B.D. Endothelin-1 gene regulation. FASEB J 2011, 25:16-28.
14. Lee M.E., Dhadly M.S., Temizer D.H., Clifford J.A., Yoshizumi M., Quertermous T. Regulation of endothelin-1 gene expression by Fos and Jun. J Biol Chem 1991, 266:19034-19039.
15. Aitsebaomo J., Kingsley-Kallesen M.L., Wu Y., Quertermous T., Patterson C. Vezf1/DB1 is an endothelial cell-specific transcription factor that regulates expression of the endothelin-1 promoter. J Biol Chem 2001, 276:39197-39205.
16. Wort S.J., Ito M., Chou P.C., Mc Master S.K., Badiger R., Jazrawi E., et al. Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappaB binding and histone acetylation at specific kappaB sites. J Biol Chem 2009, 284:24297-24305.
17. Reiter C.E., Kim J.A., Quon M.J. Green tea polyphenol epigallocatechin gallate reduces endothelin-1 expression and secretion in vascular endothelial cells: roles for AMP-activated protein kinase, Akt, and FOXO1. Endocrinology 2010, 151:103-114.
18. Kitazumi K., Tasaka K. The role of c-Jun protein in thrombin-stimulated expression of preproendothelin-1 mRNA in porcine aortic endothelial cells. Biochem Pharmacol 1993, 46:455-464.
19. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.C., Najib J., et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999, 85:394-402.
20. Hu R.M., Chuang M.Y., Prins B., Kashyap M.L., Frank H.J., Pedram A., et al. High density lipoproteins stimulate the production and secretion of endothelin-1 from cultured bovine aortic endothelial cells. J Clin Invest 1994, 93:1056-1062.
21. Earley S., Resta T.C. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol 2002, 283:L86-L93.
22. Lepailleur-Enouf D., Valdenaire O., Philippe M., Jandrot-Perrus M., Michel J.B. Thrombin induces endothelin expression in arterial smooth muscle cells. Am J Physiol Heart Circ Physiol 2000, 278:H1606-H1612.
23. He F., Li J., Mu Y., Kuruba R., Ma Z., Wilson A., et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res 2006, 98:192-199.
24. Martinez-Gonzalez J., Badimon L. The NR4A subfamily of nuclear receptors: new early genes regulated by growth factors in vascular cells. Cardiovasc Res 2005, 65:609-618.
25. van Tiel C.M., de Vries C.J. NR4All in the vessel wall. J Steroid Biochem Mol Biol 2012, 130:186-193.
26. Pires N.M., Pols T.W., de Vries M.R., van Tiel C.M., Bonta P.I., Vos M., et al. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation 2007, 115:493-500.
27. Bonta P.I., Matlung H.L., Vos M., Peters S.L., Pannekoek H., Bakker E.N., et al. Nuclear receptor Nur77 inhibits vascular outward remodelling and reduces macrophage accumulation and matrix metalloproteinase levels. Cardiovasc Res 2010, 87:561-568.
28. Zeng H., Qin L., Zhao D., Tan X., Manseau E.J., Van Hoang M., et al. Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity. J Exp Med 2006, 203:719-729.
29. You B., Jiang Y.Y., Chen S., Yan G., Sun J. The orphan nuclear receptor Nur77 suppresses endothelial cell activation through induction of IkappaBalpha expression. Circ Res 2009, 104:742-749.
30. Hamers A.A., Vos M., Rassam F., Marinkovic G., Kurakula K., van Gorp P.J., et al. Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis. Circ Res 2012, 110:428-438.
31. Hanna R.N., Shaked I., Hubbeling H.G., Punt J.A., Wu R., Herrley E., et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res 2012, 110:416-427.
32. Yoo Y.G., Na T.Y., Yang W.K., Kim H.J., Lee I.K., Kong G., et al. 6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1alpha resulting in new vessel formation. Oncogene 2007, 26:3823-3834.
33. Zhan Y., Du X., Chen H., Liu J., Zhao B., Huang D., et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat Chem Biol 2008, 4:548-556.
34. Ham J., Eilers A., Whitfield J., Neame S.J., Shah B. c-Jun and the transcriptional control of neuronal apoptosis. Biochem Pharmacol 2000, 60:1015-1021.
35. Ma C., D'Mello S.R. Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism. J Biol Chem 2011, 286:4819-4828.
36. Chang C.Z., Wu S.C., Kwan A.L., Lin C.L., Hwang S.L. 6-Mercaptopurine reverses experimental vasospasm and alleviates the production of endothelins in NO-independent mechanism-a laboratory study. Acta Neurochir (Wien) 2011, 153:939-949.
37. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:E131-E136.
38. Trejo J., Chambard J.C., Karin M., Brown J.H. Biphasic increase in c-jun mRNA is required for induction of AP-1-mediated gene transcription: differential effects of muscarinic and thrombin receptor activation. Mol Cell Biol 1992, 12:4742-4750.
39. Meng Q., Xia Y. c-Jun, at the crossroad of the signaling network. Protein Cell 2011, 2:889-898.
40. Zhang X.K. Targeting Nur77 translocation. Expert Opin Ther Targets 2007, 11:69-79.
41. Lin B., Kolluri S.K., Lin F., Liu W., Han Y.H., Cao X., et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116:527-540.
42. Dschietzig T., Richter C., Pfannenschmidt G., Bartsch C., Laule M., Baumann G., et al. Dexamethasone inhibits stimulation of pulmonary endothelins by proinflammatory cytokines: possible involvement of a nuclear factor kappa B dependent mechanism. Intensive Care Med 2001, 27:751-756.
43. Yamashita K., Discher D.J., Hu J., Bishopric N.H., Webster K.A. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J Biol Chem 2001, 276:12645-12653.